Short ragweed pollen allergen Amb a 1 (Amb a 1)

Short ragweed pollen allergen Amb a 1 is the immunodominant protein from Ambrosia artemisiifolia, acting as the primary driver of seasonal allergic rhinitis. Biologically, it is a pectate lyase enzyme that degrades plant cell walls, but its clinical significance lies in its high allergenicity. The immune system recognizes Amb a 1 through the processing of its protein into peptides, which are then presented by MHC class II molecules to T-cell receptors (TCRs). This recognition typically triggers a Th2-polarized immune response, leading to IgE production and mast cell degranulation. Therapeutic strategies like Ragwitek and experimental peptide-based vaccines target this T-cell recognition process to induce desensitization. By promoting the expansion of regulatory T cells and the production of blocking IgG4 antibodies, these therapies aim to modify the underlying disease and provide long-term relief from allergic symptoms.

Other names

Amb a 1Pectate lyaseShort ragweed allergenAmbrosia artemisiifolia allergen 1Ra1

Allergen-specific immunotherapy (AIT) induces immunological tolerance by repeatedly exposing the immune system to allergen peptides, shifting the response from Th2-mediated inflammation to Th1 or Treg-mediated regulatory responses and inducing IgG4 blocking antibodies.